TW201725203A - 作為ａｐｊ受體促效劑之雜芳基羥基嘧啶酮 - Google Patents

Info

Publication number

TW201725203A

TW201725203A TW105141572A TW105141572A TW201725203A TW 201725203 A TW201725203 A TW 201725203A TW 105141572 A TW105141572 A TW 105141572A TW 105141572 A TW105141572 A TW 105141572A TW 201725203 A TW201725203 A TW 201725203A

Authority

TW

Taiwan

Prior art keywords

independently selected

substituted

alkyl

group

cycloalkyl

Prior art date

2015-12-16

Links

• Espacenet
• Global Dossier
• Discuss

• 229940124752 APJ receptor agonist Drugs 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims abstract description 239
• 125000000217 alkyl group Chemical group 0.000 claims description 273
• 229910052801 chlorine Inorganic materials 0.000 claims description 136
• 229910052731 fluorine Inorganic materials 0.000 claims description 136
• -1 substituted Chemical class 0.000 claims description 136
• 125000000623 heterocyclic group Chemical group 0.000 claims description 103
• 229910052794 bromium Inorganic materials 0.000 claims description 93
• 229910052739 hydrogen Inorganic materials 0.000 claims description 79
• 229910052799 carbon Inorganic materials 0.000 claims description 66
• 150000003839 salts Chemical class 0.000 claims description 64
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 58
• 125000002837 carbocyclic group Chemical group 0.000 claims description 56
• 229910052760 oxygen Inorganic materials 0.000 claims description 54
• 229910052757 nitrogen Inorganic materials 0.000 claims description 50
• 125000001424 substituent group Chemical group 0.000 claims description 49
• 239000003814 drug Substances 0.000 claims description 46
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 42
• 206010019280 Heart failures Diseases 0.000 claims description 39
• 150000001721 carbon Chemical group 0.000 claims description 38
• 125000004432 carbon atom Chemical group C* 0.000 claims description 37
• 125000003342 alkenyl group Chemical group 0.000 claims description 33
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 33
• 229910052717 sulfur Inorganic materials 0.000 claims description 32
• 229910052736 halogen Inorganic materials 0.000 claims description 31
• 238000011282 treatment Methods 0.000 claims description 29
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 26
• 150000002367 halogens Chemical class 0.000 claims description 26
• 125000001072 heteroaryl group Chemical group 0.000 claims description 26
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 24
• 125000003118 aryl group Chemical group 0.000 claims description 21
• 239000008194 pharmaceutical composition Substances 0.000 claims description 21
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 19
• 125000005842 heteroatom Chemical group 0.000 claims description 19
• 125000004076 pyridyl group Chemical group 0.000 claims description 19
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 18
• 125000000304 alkynyl group Chemical group 0.000 claims description 17
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 13
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 13
• 239000003937 drug carrier Substances 0.000 claims description 13
• 125000000714 pyrimidinyl group Chemical group 0.000 claims description 12
• 206010012601 diabetes mellitus Diseases 0.000 claims description 11
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
• 125000003107 substituted aryl group Chemical group 0.000 claims description 10
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 9
• 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 8
• 208000029078 coronary artery disease Diseases 0.000 claims description 8
• 125000000392 cycloalkenyl group Chemical group 0.000 claims description 8
• 125000005843 halogen group Chemical group 0.000 claims description 8
• 125000004452 carbocyclyl group Chemical group 0.000 claims description 7
• 230000002107 myocardial effect Effects 0.000 claims description 7
• 208000010125 myocardial infarction Diseases 0.000 claims description 7
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
• 238000004519 manufacturing process Methods 0.000 claims description 6
• 208000006011 Stroke Diseases 0.000 claims description 5
• 125000002947 alkylene group Chemical group 0.000 claims description 4
• 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims description 4
• 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 claims description 3
• 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 3
• 208000006029 Cardiomegaly Diseases 0.000 claims description 3
• 208000031229 Cardiomyopathies Diseases 0.000 claims description 3
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
• 238000007634 remodeling Methods 0.000 claims description 3
• 206010061216 Infarction Diseases 0.000 claims description 2
• 208000038003 heart failure with preserved ejection fraction Diseases 0.000 claims description 2
• 230000007574 infarction Effects 0.000 claims description 2
• 229910004013 NO 2 Inorganic materials 0.000 claims 11
• 125000006164 6-membered heteroaryl group Chemical group 0.000 claims 2
• 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 2
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
• 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
• LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims 1
• 208000003037 Diastolic Heart Failure Diseases 0.000 claims 1
• 208000008253 Systolic Heart Failure Diseases 0.000 claims 1
• 238000007675 cardiac surgery Methods 0.000 claims 1
• 208000018578 heart valve disease Diseases 0.000 claims 1
• 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
• 239000000203 mixture Substances 0.000 abstract description 45
• 239000000556 agonist Substances 0.000 abstract description 10
• 239000008177 pharmaceutical agent Substances 0.000 abstract description 2
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 198
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 153
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 125
• 239000000460 chlorine Substances 0.000 description 95
• 238000000034 method Methods 0.000 description 88
• 235000019439 ethyl acetate Nutrition 0.000 description 73
• 239000011541 reaction mixture Substances 0.000 description 64
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 47
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 40
• 239000003795 chemical substances by application Substances 0.000 description 39
• 101000793362 Homo sapiens Apelin receptor Proteins 0.000 description 36
• 239000000243 solution Substances 0.000 description 34
• 102100030949 Apelin receptor Human genes 0.000 description 33
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
• 239000012453 solvate Substances 0.000 description 32
• 229940124597 therapeutic agent Drugs 0.000 description 32
• 238000005481 NMR spectroscopy Methods 0.000 description 31
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
• 201000010099 disease Diseases 0.000 description 29
• 239000012071 phase Substances 0.000 description 29
• 230000002829 reductive effect Effects 0.000 description 27
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 24
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 23
• IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 23
• 229940095074 cyclic amp Drugs 0.000 description 23
• 239000000651 prodrug Substances 0.000 description 22
• 229940002612 prodrug Drugs 0.000 description 22
• 239000002904 solvent Substances 0.000 description 22
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 21
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 17
• 239000002585 base Substances 0.000 description 16
• 230000000694 effects Effects 0.000 description 16
• 238000002360 preparation method Methods 0.000 description 16
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
• 238000006243 chemical reaction Methods 0.000 description 15
• OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 15
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
• 101100323464 Homo sapiens APLNR gene Proteins 0.000 description 13
• 239000004480 active ingredient Substances 0.000 description 13
• 230000014759 maintenance of location Effects 0.000 description 13
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 13
• 239000000126 substance Substances 0.000 description 13
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 12
• 239000012267 brine Substances 0.000 description 12
• 150000002148 esters Chemical class 0.000 description 12
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
• 108091008803 APLNR Proteins 0.000 description 11
• 230000002265 prevention Effects 0.000 description 11
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
• 229940079593 drug Drugs 0.000 description 10
• 239000002245 particle Substances 0.000 description 10
• 238000003786 synthesis reaction Methods 0.000 description 10
• 238000005160 1H NMR spectroscopy Methods 0.000 description 9
• 206010020772 Hypertension Diseases 0.000 description 9
• 230000000747 cardiac effect Effects 0.000 description 9
• 239000003153 chemical reaction reagent Substances 0.000 description 9
• 230000000670 limiting effect Effects 0.000 description 9
• 230000008569 process Effects 0.000 description 9
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 8
• 239000005695 Ammonium acetate Substances 0.000 description 8
• OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 8
• 235000019257 ammonium acetate Nutrition 0.000 description 8
• 229940043376 ammonium acetate Drugs 0.000 description 8
• 238000003556 assay Methods 0.000 description 8
• 125000004429 atom Chemical group 0.000 description 8
• 239000012044 organic layer Substances 0.000 description 8
• 125000002971 oxazolyl group Chemical group 0.000 description 8
• 239000007787 solid Substances 0.000 description 8
• 102000018746 Apelin Human genes 0.000 description 7
• 108010052412 Apelin Proteins 0.000 description 7
• 201000001320 Atherosclerosis Diseases 0.000 description 7
• 208000008589 Obesity Diseases 0.000 description 7
• 125000003545 alkoxy group Chemical group 0.000 description 7
• 239000003472 antidiabetic agent Substances 0.000 description 7
• BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 description 7
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 7
• 235000020824 obesity Nutrition 0.000 description 7
• 238000002953 preparative HPLC Methods 0.000 description 7
• 238000000746 purification Methods 0.000 description 7
• 229920006395 saturated elastomer Polymers 0.000 description 7
• 238000006467 substitution reaction Methods 0.000 description 7
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
• 208000004476 Acute Coronary Syndrome Diseases 0.000 description 6
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 239000013543 active substance Substances 0.000 description 6
• 125000002618 bicyclic heterocycle group Chemical group 0.000 description 6
• 239000002552 dosage form Substances 0.000 description 6
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
• 125000000842 isoxazolyl group Chemical group 0.000 description 6
• 125000002950 monocyclic group Chemical group 0.000 description 6
• 125000003226 pyrazolyl group Chemical group 0.000 description 6
• 208000037803 restenosis Diseases 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• 125000001544 thienyl group Chemical group 0.000 description 6
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
• 206010002383 Angina Pectoris Diseases 0.000 description 5
• 241000124008 Mammalia Species 0.000 description 5
• 150000001412 amines Chemical class 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 229940125708 antidiabetic agent Drugs 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 5
• 235000008504 concentrate Nutrition 0.000 description 5
• 239000012141 concentrate Substances 0.000 description 5
• 238000001514 detection method Methods 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 125000002541 furyl group Chemical group 0.000 description 5
• 125000001188 haloalkyl group Chemical group 0.000 description 5
• 150000002430 hydrocarbons Chemical group 0.000 description 5
• 239000001257 hydrogen Substances 0.000 description 5
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
• 125000002883 imidazolyl group Chemical group 0.000 description 5
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 5
• 208000028867 ischemia Diseases 0.000 description 5
• 230000007774 longterm Effects 0.000 description 5
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 208000031225 myocardial ischemia Diseases 0.000 description 5
• 239000012074 organic phase Substances 0.000 description 5
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 5
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
• 108090000765 processed proteins & peptides Proteins 0.000 description 5
• 208000002815 pulmonary hypertension Diseases 0.000 description 5
• 125000003373 pyrazinyl group Chemical group 0.000 description 5
• 125000000168 pyrrolyl group Chemical group 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• 125000001113 thiadiazolyl group Chemical group 0.000 description 5
• 125000000335 thiazolyl group Chemical group 0.000 description 5
• 230000002792 vascular Effects 0.000 description 5
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
• 229940127291 Calcium channel antagonist Drugs 0.000 description 4
• SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 4
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
• 208000031226 Hyperlipidaemia Diseases 0.000 description 4
• 208000001145 Metabolic Syndrome Diseases 0.000 description 4
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
• 206010063837 Reperfusion injury Diseases 0.000 description 4
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 4
• 125000001931 aliphatic group Chemical group 0.000 description 4
• 229910052783 alkali metal Inorganic materials 0.000 description 4
• 238000002399 angioplasty Methods 0.000 description 4
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 4
• 125000002619 bicyclic group Chemical group 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 239000000480 calcium channel blocker Substances 0.000 description 4
• OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 4
• 230000008878 coupling Effects 0.000 description 4
• 238000010168 coupling process Methods 0.000 description 4
• 238000005859 coupling reaction Methods 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 239000002934 diuretic Substances 0.000 description 4
• 239000000284 extract Substances 0.000 description 4
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
• 125000004438 haloalkoxy group Chemical group 0.000 description 4
• 230000007062 hydrolysis Effects 0.000 description 4
• 238000006460 hydrolysis reaction Methods 0.000 description 4
• 125000002632 imidazolidinyl group Chemical group 0.000 description 4
• 238000001802 infusion Methods 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 125000002757 morpholinyl group Chemical group 0.000 description 4
• 125000001624 naphthyl group Chemical group 0.000 description 4
• 125000001715 oxadiazolyl group Chemical group 0.000 description 4
• 125000000160 oxazolidinyl group Chemical group 0.000 description 4
• 125000004430 oxygen atom Chemical group O* 0.000 description 4
• 239000004033 plastic Substances 0.000 description 4
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
• 239000000047 product Substances 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• 125000002098 pyridazinyl group Chemical group 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 238000012552 review Methods 0.000 description 4
• 125000004434 sulfur atom Chemical group 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 125000003831 tetrazolyl group Chemical group 0.000 description 4
• 125000004306 triazinyl group Chemical group 0.000 description 4
• 125000001425 triazolyl group Chemical group 0.000 description 4
• AGZPNUZBDCYTBB-UHFFFAOYSA-N triethyl methanetricarboxylate Chemical compound CCOC(=O)C(C(=O)OCC)C(=O)OCC AGZPNUZBDCYTBB-UHFFFAOYSA-N 0.000 description 4
• 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
• 239000003643 water by type Substances 0.000 description 4
• CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 3
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 3
• ZLCPKMIJYMHZMJ-UHFFFAOYSA-N 2-nitrobenzene-1,3-diol Chemical compound OC1=CC=CC(O)=C1[N+]([O-])=O ZLCPKMIJYMHZMJ-UHFFFAOYSA-N 0.000 description 3
• 239000005541 ACE inhibitor Substances 0.000 description 3
• 102400000345 Angiotensin-2 Human genes 0.000 description 3
• 206010003658 Atrial Fibrillation Diseases 0.000 description 3
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
• WMCRVHLXPDMMSC-UHFFFAOYSA-N C1(CC1)CCC=1N(C(=C(C(N=1)=O)C1=NN=C(O1)CC(=O)N(CC)CC)O)C1=C(C=CC=C1OC)OC Chemical compound C1(CC1)CCC=1N(C(=C(C(N=1)=O)C1=NN=C(O1)CC(=O)N(CC)CC)O)C1=C(C=CC=C1OC)OC WMCRVHLXPDMMSC-UHFFFAOYSA-N 0.000 description 3
• 206010007556 Cardiac failure acute Diseases 0.000 description 3
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
• 241000208011 Digitalis Species 0.000 description 3
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
• 208000035150 Hypercholesterolemia Diseases 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 3
• UQSPDQBZYCFYTL-UHFFFAOYSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)CCCC)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)CCCC)=O UQSPDQBZYCFYTL-UHFFFAOYSA-N 0.000 description 3
• CQIXTCOZPWAVCI-UHFFFAOYSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OCC)OCC)CCCC)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OCC)OCC)CCCC)=O CQIXTCOZPWAVCI-UHFFFAOYSA-N 0.000 description 3
• 208000018262 Peripheral vascular disease Diseases 0.000 description 3
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 229940083712 aldosterone antagonist Drugs 0.000 description 3
• 125000006242 amine protecting group Chemical group 0.000 description 3
• 229950006323 angiotensin ii Drugs 0.000 description 3
• 239000000883 anti-obesity agent Substances 0.000 description 3
• 229940125710 antiobesity agent Drugs 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 3
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 3
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
• 239000002327 cardiovascular agent Substances 0.000 description 3
• 229940125692 cardiovascular agent Drugs 0.000 description 3
• 210000004027 cell Anatomy 0.000 description 3
• 230000001684 chronic effect Effects 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000009833 condensation Methods 0.000 description 3
• 230000005494 condensation Effects 0.000 description 3
• 230000008602 contraction Effects 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
• NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 3
• 206010061428 decreased appetite Diseases 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 229940030606 diuretics Drugs 0.000 description 3
• 238000001035 drying Methods 0.000 description 3
• 239000002702 enteric coating Substances 0.000 description 3
• 238000009505 enteric coating Methods 0.000 description 3
• 239000000706 filtrate Substances 0.000 description 3
• 238000001914 filtration Methods 0.000 description 3
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 3
• 125000000524 functional group Chemical group 0.000 description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 description 3
• 229940093915 gynecological organic acid Drugs 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 239000000543 intermediate Substances 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 150000007522 mineralic acids Chemical class 0.000 description 3
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 150000007524 organic acids Chemical class 0.000 description 3
• 235000005985 organic acids Nutrition 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 239000000123 paper Substances 0.000 description 3
• 125000004193 piperazinyl group Chemical group 0.000 description 3
• 125000003386 piperidinyl group Chemical group 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 238000009117 preventive therapy Methods 0.000 description 3
• 238000011321 prophylaxis Methods 0.000 description 3
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
• 125000005493 quinolyl group Chemical group 0.000 description 3
• 239000003087 receptor blocking agent Substances 0.000 description 3
• 229910052938 sodium sulfate Inorganic materials 0.000 description 3
• 235000011152 sodium sulphate Nutrition 0.000 description 3
• 239000011593 sulfur Substances 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 3
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
• CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
• 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 3
• OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
• HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 2
• PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 2
• 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 2
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
• BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 2
• DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 2
• BVSIAYQIMUUCRW-UHFFFAOYSA-N 2-(1,2-benzoxazol-3-yl)acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=NOC2=C1 BVSIAYQIMUUCRW-UHFFFAOYSA-N 0.000 description 2
• VGOALPIDEXVYQI-UHFFFAOYSA-N 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-n-[3-imidazol-1-yl-5-(trifluoromethyl)phenyl]-4-methylbenzamide Chemical compound C1=C(C#CC=2N3N=CC=CC3=NC=2)C(C)=CC=C1C(=O)NC(C=C(C=1)C(F)(F)F)=CC=1N1C=CN=C1 VGOALPIDEXVYQI-UHFFFAOYSA-N 0.000 description 2
• VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 2
• YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
• MVXAKOGJWVQPKC-UHFFFAOYSA-N 5-(3-ethynyl-5-fluorophenyl)-2-pyridin-2-yl-4,6,7,8-tetrahydro-[1,3]oxazolo[4,5-c]azepine Chemical compound FC1=CC(C#C)=CC(N2CC=3N=C(OC=3CCC2)C=2N=CC=CC=2)=C1 MVXAKOGJWVQPKC-UHFFFAOYSA-N 0.000 description 2
• WJRKNLONLOMALV-UHFFFAOYSA-N 5-chloropyridine Chemical compound ClC1=C=NC=C[CH]1 WJRKNLONLOMALV-UHFFFAOYSA-N 0.000 description 2
• UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
• 108050000824 Angiotensin II receptor Proteins 0.000 description 2
• 101800000733 Angiotensin-2 Proteins 0.000 description 2
• 102400000252 Apelin-13 Human genes 0.000 description 2
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
• 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• VSGCPRZRCRMPOI-UHFFFAOYSA-N COC1=CC=CC(OC)=C1N1C(O)=C(C2=NN=C(CC3=NOC4=CC=CC=C34)O2)C(=O)N=C1CCC1CC1 Chemical compound COC1=CC=CC(OC)=C1N1C(O)=C(C2=NN=C(CC3=NOC4=CC=CC=C34)O2)C(=O)N=C1CCC1CC1 VSGCPRZRCRMPOI-UHFFFAOYSA-N 0.000 description 2
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
• 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 2
• JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
• IKDUHFVWQUJBGP-UHFFFAOYSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1C1CC1)C1CC1)CCCC)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1C1CC1)C1CC1)CCCC)=O IKDUHFVWQUJBGP-UHFFFAOYSA-N 0.000 description 2
• RFFFKMOABOFIDF-UHFFFAOYSA-N Pentanenitrile Chemical compound CCCCC#N RFFFKMOABOFIDF-UHFFFAOYSA-N 0.000 description 2
• 208000005764 Peripheral Arterial Disease Diseases 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 108010062481 Type 1 Angiotensin Receptor Proteins 0.000 description 2
• 102000010913 Type 1 Angiotensin Receptor Human genes 0.000 description 2
• 208000009982 Ventricular Dysfunction Diseases 0.000 description 2
• LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 150000008065 acid anhydrides Chemical class 0.000 description 2
• 239000012190 activator Substances 0.000 description 2
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 230000008484 agonism Effects 0.000 description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
• 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
• 208000022531 anorexia Diseases 0.000 description 2
• 230000003063 anti-neuropathic effect Effects 0.000 description 2
• 230000002946 anti-pancreatic effect Effects 0.000 description 2
• 230000003324 anti-retinal effect Effects 0.000 description 2
• 229940030600 antihypertensive agent Drugs 0.000 description 2
• 239000002220 antihypertensive agent Substances 0.000 description 2
• 239000003524 antilipemic agent Substances 0.000 description 2
• XXCCRHIAIBQDPX-PEWBXTNBSA-N apelin-13 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(N)=O)C1=CN=CN1 XXCCRHIAIBQDPX-PEWBXTNBSA-N 0.000 description 2
• 108010040480 apelin-13 peptide Proteins 0.000 description 2
• 239000000010 aprotic solvent Substances 0.000 description 2
• 239000008346 aqueous phase Substances 0.000 description 2
• 239000012131 assay buffer Substances 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 2
• 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 2
• 125000005605 benzo group Chemical group 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
• 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
• 239000002876 beta blocker Substances 0.000 description 2
• 229940097320 beta blocking agent Drugs 0.000 description 2
• 239000011111 cardboard Substances 0.000 description 2
• 239000003054 catalyst Substances 0.000 description 2
• 208000026106 cerebrovascular disease Diseases 0.000 description 2
• 239000003638 chemical reducing agent Substances 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 239000002475 cognitive enhancer Substances 0.000 description 2
• 229940125904 compound 1 Drugs 0.000 description 2
• 229940127204 compound 29 Drugs 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 2
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 2
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
• NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
• FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• 229960001089 dobutamine Drugs 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 239000006274 endogenous ligand Substances 0.000 description 2
• 150000002170 ethers Chemical class 0.000 description 2
• 239000000835 fiber Substances 0.000 description 2
• QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
• 230000009760 functional impairment Effects 0.000 description 2
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 229960000346 gliclazide Drugs 0.000 description 2
• 239000003292 glue Substances 0.000 description 2
• ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 210000005003 heart tissue Anatomy 0.000 description 2
• 230000000004 hemodynamic effect Effects 0.000 description 2
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
• 125000005945 imidazopyridyl group Chemical group 0.000 description 2
• 239000012442 inert solvent Substances 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 210000000936 intestine Anatomy 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 230000000302 ischemic effect Effects 0.000 description 2
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
• 125000005956 isoquinolyl group Chemical group 0.000 description 2
• 125000001786 isothiazolyl group Chemical group 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 239000007937 lozenge Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 239000003695 memory enhancer Substances 0.000 description 2
• VSEAAEQOQBMPQF-UHFFFAOYSA-N morpholin-3-one Chemical compound O=C1COCCN1 VSEAAEQOQBMPQF-UHFFFAOYSA-N 0.000 description 2
• 150000002823 nitrates Chemical class 0.000 description 2
• JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
• 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 2
• 239000006186 oral dosage form Substances 0.000 description 2
• 150000002923 oximes Chemical class 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• 229940127557 pharmaceutical product Drugs 0.000 description 2
• DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
• 230000001766 physiological effect Effects 0.000 description 2
• SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
• 125000003367 polycyclic group Chemical group 0.000 description 2
• 150000004032 porphyrins Chemical class 0.000 description 2
• 229910000027 potassium carbonate Inorganic materials 0.000 description 2
• 230000009862 primary prevention Effects 0.000 description 2
• 239000001294 propane Substances 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 102000004169 proteins and genes Human genes 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 239000002461 renin inhibitor Substances 0.000 description 2
• 229940086526 renin-inhibitors Drugs 0.000 description 2
• 238000004007 reversed phase HPLC Methods 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 230000009863 secondary prevention Effects 0.000 description 2
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
• QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 238000004611 spectroscopical analysis Methods 0.000 description 2
• 150000003413 spiro compounds Chemical class 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 150000003512 tertiary amines Chemical class 0.000 description 2
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 238000000844 transformation Methods 0.000 description 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
• 230000024883 vasodilation Effects 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 230000006815 ventricular dysfunction Effects 0.000 description 2
• 239000008096 xylene Substances 0.000 description 2
• DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
• XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
• DAAXYQZSKBPJOX-FQEVSTJZSA-N (2S)-2-amino-3-[4-[5-[3-(4-hydroxyphenyl)-4-methoxyphenyl]-1,2,4-oxadiazol-3-yl]phenyl]propanoic acid Chemical compound COC1=C(C=C(C=C1)C2=NC(=NO2)C3=CC=C(C=C3)C[C@@H](C(=O)O)N)C4=CC=C(C=C4)O DAAXYQZSKBPJOX-FQEVSTJZSA-N 0.000 description 1
• MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
• STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
• 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 1
• 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
• FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
• 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
• PKORYTIUMAOPED-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinazoline Chemical compound C1=CC=C2NCNCC2=C1 PKORYTIUMAOPED-UHFFFAOYSA-N 0.000 description 1
• 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
• 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
• 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
• BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
• 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
• 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
• 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
• KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
• 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 description 1
• FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
• 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
• VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
• DNNLLVKQTRCODG-UHFFFAOYSA-N 1,3-bis(2-chloroethoxy)-2-nitrobenzene Chemical compound ClCCOC1=C(C(=CC=C1)OCCCl)[N+](=O)[O-] DNNLLVKQTRCODG-UHFFFAOYSA-N 0.000 description 1
• DVARRUNMHGTJQO-UHFFFAOYSA-N 1,3-dicyclopropyloxy-2-nitrobenzene Chemical compound [O-][N+](=O)c1c(OC2CC2)cccc1OC1CC1 DVARRUNMHGTJQO-UHFFFAOYSA-N 0.000 description 1
• UGQDAAPDTCVIJY-UHFFFAOYSA-N 1,3-diethoxy-2-nitrobenzene Chemical compound C(C)OC1=C(C(=CC=C1)OCC)[N+](=O)[O-] UGQDAAPDTCVIJY-UHFFFAOYSA-N 0.000 description 1
• ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
• LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
• 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
• AQFLVLHRZFLDDV-UHFFFAOYSA-N 1-phenylpropan-1-amine Chemical compound CCC(N)C1=CC=CC=C1 AQFLVLHRZFLDDV-UHFFFAOYSA-N 0.000 description 1
• 125000006017 1-propenyl group Chemical group 0.000 description 1
• WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
• 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
• WBWYXWILSHQILH-UHFFFAOYSA-N 2,2-dimethyldecane Chemical compound CCCCCCCCC(C)(C)C WBWYXWILSHQILH-UHFFFAOYSA-N 0.000 description 1
• QDKSGHXRHXVMPF-UHFFFAOYSA-N 2,2-dimethylundecane Chemical compound CCCCCCCCCC(C)(C)C QDKSGHXRHXVMPF-UHFFFAOYSA-N 0.000 description 1
• LCZASQOOGUQRIA-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane Chemical compound CCCP1OP(CCC)OP(CCC)O1 LCZASQOOGUQRIA-UHFFFAOYSA-N 0.000 description 1
• BTWJHXDDGRUVCN-UHFFFAOYSA-N 2,6-dicyclopropylaniline Chemical compound C1(CC1)C1=C(N)C(=CC=C1)C1CC1 BTWJHXDDGRUVCN-UHFFFAOYSA-N 0.000 description 1
• NNGNUXTUSIPQKI-UHFFFAOYSA-N 2,6-dicyclopropyloxyaniline Chemical compound C1(CC1)OC1=C(N)C(=CC=C1)OC1CC1 NNGNUXTUSIPQKI-UHFFFAOYSA-N 0.000 description 1
• XHNDTWIUBZHABC-UHFFFAOYSA-N 2,6-diethoxyaniline Chemical compound CCOC1=CC=CC(OCC)=C1N XHNDTWIUBZHABC-UHFFFAOYSA-N 0.000 description 1
• HQBJSEKQNRSDAZ-UHFFFAOYSA-N 2,6-dimethoxyaniline Chemical compound COC1=CC=CC(OC)=C1N HQBJSEKQNRSDAZ-UHFFFAOYSA-N 0.000 description 1
• QFBYQIUBLBNTDO-UHFFFAOYSA-N 2-(2,6-dimethoxyphenyl)acetic acid Chemical compound COC1=CC=CC(OC)=C1CC(O)=O QFBYQIUBLBNTDO-UHFFFAOYSA-N 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• UQZPGHOJMQTOHB-UHFFFAOYSA-N 2-chloro-n-(2-chloroethyl)-n-ethylethanamine Chemical compound ClCCN(CC)CCCl UQZPGHOJMQTOHB-UHFFFAOYSA-N 0.000 description 1
• ZXNMIUJDTOMBPV-UHFFFAOYSA-N 2-chloroethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCCl)C=C1 ZXNMIUJDTOMBPV-UHFFFAOYSA-N 0.000 description 1
• LUNMJRJMSXZSLC-UHFFFAOYSA-N 2-cyclopropylethanol Chemical compound OCCC1CC1 LUNMJRJMSXZSLC-UHFFFAOYSA-N 0.000 description 1
• JVOCWIRGDNWGKH-UHFFFAOYSA-N 2-cyclopropylethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCC1CC1 JVOCWIRGDNWGKH-UHFFFAOYSA-N 0.000 description 1
• OAAKFAXUEYTMHF-UHFFFAOYSA-N 2-ethoxyacetamide Chemical compound CCOCC(N)=O OAAKFAXUEYTMHF-UHFFFAOYSA-N 0.000 description 1
• WPYUCWSMVJJWFI-UHFFFAOYSA-N 2-ethoxyacetonitrile Chemical compound CCOCC#N WPYUCWSMVJJWFI-UHFFFAOYSA-N 0.000 description 1
• 125000006040 2-hexenyl group Chemical group 0.000 description 1
• HKOJYPPTIPJZAZ-UHFFFAOYSA-N 2-methoxy-6-methylaniline Chemical compound COC1=CC=CC(C)=C1N HKOJYPPTIPJZAZ-UHFFFAOYSA-N 0.000 description 1
• ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 1
• 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
• CFBYEGUGFPZCNF-UHFFFAOYSA-N 2-nitroanisole Chemical compound COC1=CC=CC=C1[N+]([O-])=O CFBYEGUGFPZCNF-UHFFFAOYSA-N 0.000 description 1
• 125000006024 2-pentenyl group Chemical group 0.000 description 1
• WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• YZTCGYARZGKANI-UHFFFAOYSA-N 3-(diethylamino)-1-phenylpropan-1-one Chemical compound CCN(CC)CCC(=O)C1=CC=CC=C1 YZTCGYARZGKANI-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• INDZKZONOLGFIL-UHFFFAOYSA-N 3-cyclopropylpropanenitrile Chemical compound N#CCCC1CC1 INDZKZONOLGFIL-UHFFFAOYSA-N 0.000 description 1
• 125000006041 3-hexenyl group Chemical group 0.000 description 1
• HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
• 125000006042 4-hexenyl group Chemical group 0.000 description 1
• 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
• IBENILMLQGLCTI-MRXNPFEDSA-N 5-[5-(1,2-benzoxazol-3-ylmethyl)-1,3,4-oxadiazol-2-yl]-2-butyl-6-hydroxy-3-[(1R)-1-(2-methoxyphenyl)ethyl]pyrimidin-4-one Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)[C@H](C)C1=C(C=CC=C1)OC)=O IBENILMLQGLCTI-MRXNPFEDSA-N 0.000 description 1
• 125000006043 5-hexenyl group Chemical group 0.000 description 1
• 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
• 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 101150059573 AGTR1 gene Proteins 0.000 description 1
• ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
• 102000008873 Angiotensin II receptor Human genes 0.000 description 1
• 208000026828 Aorta coarctation Diseases 0.000 description 1
• 208000006179 Aortic Coarctation Diseases 0.000 description 1
• 102000016555 Apelin receptors Human genes 0.000 description 1
• 102400000251 Apelin-36 Human genes 0.000 description 1
• 101800001808 Apelin-36 Proteins 0.000 description 1
• 206010003225 Arteriospasm coronary Diseases 0.000 description 1
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
• 241000937413 Axia Species 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 229940123208 Biguanide Drugs 0.000 description 1
• XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
• 102000013585 Bombesin Human genes 0.000 description 1
• 108010051479 Bombesin Proteins 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• DJSVVGRAXDEFHU-UHFFFAOYSA-N BrC1=C(N)C(=CC=C1)Br.C1(CC1)C1=C(N)C(=CC=C1)C1CC1 Chemical compound BrC1=C(N)C(=CC=C1)Br.C1(CC1)C1=C(N)C(=CC=C1)C1CC1 DJSVVGRAXDEFHU-UHFFFAOYSA-N 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• HTBOYGSCRSWFJA-UHFFFAOYSA-N C(C1=CC=CC=C1)N1N=CC(=C1)C=1C(N(C(=NC=1O)CCCC)C1=C(C=CC=C1OC)OC)=O Chemical compound C(C1=CC=CC=C1)N1N=CC(=C1)C=1C(N(C(=NC=1O)CCCC)C1=C(C=CC=C1OC)OC)=O HTBOYGSCRSWFJA-UHFFFAOYSA-N 0.000 description 1
• ZRSIMRRIMMJHGT-UHFFFAOYSA-N C(CC=C)C=1N(C(=C(C(N=1)=O)C=1OC(=NN=1)CC1=NC(=NO1)C1=NC=CC=C1)O)C1=C(C=CC=C1OC)OC Chemical compound C(CC=C)C=1N(C(=C(C(N=1)=O)C=1OC(=NN=1)CC1=NC(=NO1)C1=NC=CC=C1)O)C1=C(C=CC=C1OC)OC ZRSIMRRIMMJHGT-UHFFFAOYSA-N 0.000 description 1
• WFACTEDYJWUDLJ-UHFFFAOYSA-N C(CCC)C1=NC(=C(C(N1C(C(C)C)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)Cl)O Chemical compound C(CCC)C1=NC(=C(C(N1C(C(C)C)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)Cl)O WFACTEDYJWUDLJ-UHFFFAOYSA-N 0.000 description 1
• BBUMQEWQESEOFA-UHFFFAOYSA-N C(CCC)C1=NC(=C(C(N1C(C(C)C)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC=1N=C(SC=1)C)O Chemical compound C(CCC)C1=NC(=C(C(N1C(C(C)C)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC=1N=C(SC=1)C)O BBUMQEWQESEOFA-UHFFFAOYSA-N 0.000 description 1
• PIXROMBOTMUZMB-UHFFFAOYSA-N C(CCC)C1=NC(=C(C(N1C(C)C=1C=NC=CC=1)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)Cl)O Chemical compound C(CCC)C1=NC(=C(C(N1C(C)C=1C=NC=CC=1)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)Cl)O PIXROMBOTMUZMB-UHFFFAOYSA-N 0.000 description 1
• ZSJFHPVXHKIXQP-UHFFFAOYSA-N C(CCC)C1=NC(=C(C(N1C(C)C=1C=NC=CC=1)=O)C=1OC(=NN=1)CC=1N=C(SC=1)C)O Chemical compound C(CCC)C1=NC(=C(C(N1C(C)C=1C=NC=CC=1)=O)C=1OC(=NN=1)CC=1N=C(SC=1)C)O ZSJFHPVXHKIXQP-UHFFFAOYSA-N 0.000 description 1
• GHWPXRHJKGYJCL-UHFFFAOYSA-N C(CCC)C1=NC(=C(C(N1C1=C(C=CC=C1OC)OC)=O)C=1C=NN(C=1)CC1=CC=C(C=C1)Cl)O Chemical compound C(CCC)C1=NC(=C(C(N1C1=C(C=CC=C1OC)OC)=O)C=1C=NN(C=1)CC1=CC=C(C=C1)Cl)O GHWPXRHJKGYJCL-UHFFFAOYSA-N 0.000 description 1
• HGODFKHCVRSQSS-HNNXBMFYSA-N C(CCC)C1=NC(=C(C(N1[C@@H](C)C1=CC(=CC=C1)OC)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)Cl)O Chemical compound C(CCC)C1=NC(=C(C(N1[C@@H](C)C1=CC(=CC=C1)OC)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)Cl)O HGODFKHCVRSQSS-HNNXBMFYSA-N 0.000 description 1
• UCAUMZAHBRKIJF-AWEZNQCLSA-N C(CCC)C1=NC(=C(C(N1[C@@H](C)C1=CC=C(C=C1)F)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)Cl)O Chemical compound C(CCC)C1=NC(=C(C(N1[C@@H](C)C1=CC=C(C=C1)F)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)Cl)O UCAUMZAHBRKIJF-AWEZNQCLSA-N 0.000 description 1
• VCSXDRYKIWULQZ-ZDUSSCGKSA-N C(CCC)C1=NC(=C(C(N1[C@@H](C)C1=CC=C(C=C1)F)=O)C=1OC(=NN=1)CC=1N=C(SC=1)C)O Chemical compound C(CCC)C1=NC(=C(C(N1[C@@H](C)C1=CC=C(C=C1)F)=O)C=1OC(=NN=1)CC=1N=C(SC=1)C)O VCSXDRYKIWULQZ-ZDUSSCGKSA-N 0.000 description 1
• ULPPTQXIFDOULD-HNNXBMFYSA-N C(CCC)C1=NC(=C(C(N1[C@@H](C)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)Cl)O Chemical compound C(CCC)C1=NC(=C(C(N1[C@@H](C)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)Cl)O ULPPTQXIFDOULD-HNNXBMFYSA-N 0.000 description 1
• CAJUADQQHLOWGI-AWEZNQCLSA-N C(CCC)C1=NC(=C(C(N1[C@@H](C)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC=1N=C(SC=1)C)O Chemical compound C(CCC)C1=NC(=C(C(N1[C@@H](C)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC=1N=C(SC=1)C)O CAJUADQQHLOWGI-AWEZNQCLSA-N 0.000 description 1
• XEGVFCIYLFJGNY-ZDUSSCGKSA-N C(CCC)C1=NC(=C(C(N1[C@@H](C)C1CC1)=O)C=1OC(=NN=1)CC1=CC=C(C=C1)Cl)O Chemical compound C(CCC)C1=NC(=C(C(N1[C@@H](C)C1CC1)=O)C=1OC(=NN=1)CC1=CC=C(C=C1)Cl)O XEGVFCIYLFJGNY-ZDUSSCGKSA-N 0.000 description 1
• JJDSBXGSQPMOGI-FQEVSTJZSA-N C(CCC)C1=NC(=C(C(N1[C@@H](CC)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC1=CC=C(C=C1)Cl)O Chemical compound C(CCC)C1=NC(=C(C(N1[C@@H](CC)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC1=CC=C(C=C1)Cl)O JJDSBXGSQPMOGI-FQEVSTJZSA-N 0.000 description 1
• RGFSVHZTUZFQLL-IBGZPJMESA-N C(CCC)C1=NC(=C(C(N1[C@@H](CC)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)Cl)O Chemical compound C(CCC)C1=NC(=C(C(N1[C@@H](CC)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)Cl)O RGFSVHZTUZFQLL-IBGZPJMESA-N 0.000 description 1
• MOQXCLBVTAOJOD-SFHVURJKSA-N C(CCC)C1=NC(=C(C(N1[C@@H](CC)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC=1N=C(SC=1)C)O Chemical compound C(CCC)C1=NC(=C(C(N1[C@@H](CC)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC=1N=C(SC=1)C)O MOQXCLBVTAOJOD-SFHVURJKSA-N 0.000 description 1
• ABXROTYIZABWRF-IBGZPJMESA-N C(CCC)C1=NC(=C(C(N1[C@@H](COC)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)Cl)O Chemical compound C(CCC)C1=NC(=C(C(N1[C@@H](COC)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)Cl)O ABXROTYIZABWRF-IBGZPJMESA-N 0.000 description 1
• OAMIJXRKLULGPY-MRXNPFEDSA-N C(CCC)C1=NC(=C(C(N1[C@H](C)C1=C(C=CC=C1)OC)=O)C=1OC(=NN=1)CC1=CC=C(C=C1)Cl)O Chemical compound C(CCC)C1=NC(=C(C(N1[C@H](C)C1=C(C=CC=C1)OC)=O)C=1OC(=NN=1)CC1=CC=C(C=C1)Cl)O OAMIJXRKLULGPY-MRXNPFEDSA-N 0.000 description 1
• PNNIJYGZLUGNRH-MRXNPFEDSA-N C(CCC)C1=NC(=C(C(N1[C@H](C)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC1=CC=C(C=C1)Cl)O Chemical compound C(CCC)C1=NC(=C(C(N1[C@H](C)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC1=CC=C(C=C1)Cl)O PNNIJYGZLUGNRH-MRXNPFEDSA-N 0.000 description 1
• ULPPTQXIFDOULD-OAHLLOKOSA-N C(CCC)C1=NC(=C(C(N1[C@H](C)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)Cl)O Chemical compound C(CCC)C1=NC(=C(C(N1[C@H](C)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)Cl)O ULPPTQXIFDOULD-OAHLLOKOSA-N 0.000 description 1
• CAJUADQQHLOWGI-CQSZACIVSA-N C(CCC)C1=NC(=C(C(N1[C@H](C)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC=1N=C(SC=1)C)O Chemical compound C(CCC)C1=NC(=C(C(N1[C@H](C)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC=1N=C(SC=1)C)O CAJUADQQHLOWGI-CQSZACIVSA-N 0.000 description 1
• JJDSBXGSQPMOGI-HXUWFJFHSA-N C(CCC)C1=NC(=C(C(N1[C@H](CC)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC1=CC=C(C=C1)Cl)O Chemical compound C(CCC)C1=NC(=C(C(N1[C@H](CC)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC1=CC=C(C=C1)Cl)O JJDSBXGSQPMOGI-HXUWFJFHSA-N 0.000 description 1
• MOQXCLBVTAOJOD-GOSISDBHSA-N C(CCC)C1=NC(=C(C(N1[C@H](CC)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC=1N=C(SC=1)C)O Chemical compound C(CCC)C1=NC(=C(C(N1[C@H](CC)C1=CC=CC=C1)=O)C=1OC(=NN=1)CC=1N=C(SC=1)C)O MOQXCLBVTAOJOD-GOSISDBHSA-N 0.000 description 1
• DLXIIUHCSBWTKT-UHFFFAOYSA-N C(CCC)C=1N(C(=C(C(N=1)=O)C=1OC(=NN=1)CC1=CC=C(C=C1)Cl)O)C1=C(C=CC=C1OC1CC1)OC1CC1 Chemical compound C(CCC)C=1N(C(=C(C(N=1)=O)C=1OC(=NN=1)CC1=CC=C(C=C1)Cl)O)C1=C(C=CC=C1OC1CC1)OC1CC1 DLXIIUHCSBWTKT-UHFFFAOYSA-N 0.000 description 1
• TZKAZXPKUCDKAV-UHFFFAOYSA-N C(CCC)C=1N(C(=C(C(N=1)=O)C=1OC(=NN=1)CC1=CC=C(C=C1)Cl)O)C1=C(C=CC=C1OCC)OCC Chemical compound C(CCC)C=1N(C(=C(C(N=1)=O)C=1OC(=NN=1)CC1=CC=C(C=C1)Cl)O)C1=C(C=CC=C1OCC)OCC TZKAZXPKUCDKAV-UHFFFAOYSA-N 0.000 description 1
• FYNYWEIOUXVDCL-UHFFFAOYSA-N C(CCC)C=1N(C(=C(C(N=1)=O)C=1OC(=NN=1)CC=1N=C(SC=1)C)O)C1=C(C=CC=C1OC)OC Chemical compound C(CCC)C=1N(C(=C(C(N=1)=O)C=1OC(=NN=1)CC=1N=C(SC=1)C)O)C1=C(C=CC=C1OC)OC FYNYWEIOUXVDCL-UHFFFAOYSA-N 0.000 description 1
• NSRZFEALDADTQK-UHFFFAOYSA-N C(CCC)C=1N(C(=C(C(N=1)=O)C=1OC(=NN=1)CC=1N=C(SC=1)C)O)C1=C(C=CC=C1OCC)OCC Chemical compound C(CCC)C=1N(C(=C(C(N=1)=O)C=1OC(=NN=1)CC=1N=C(SC=1)C)O)C1=C(C=CC=C1OCC)OCC NSRZFEALDADTQK-UHFFFAOYSA-N 0.000 description 1
• ZRQGGDRZOPVOSL-UHFFFAOYSA-N C(CCC)C=1N(C(=CC(N=1)=O)O)C1=C(C=CC=C1OC)OC Chemical compound C(CCC)C=1N(C(=CC(N=1)=O)O)C1=C(C=CC=C1OC)OC ZRQGGDRZOPVOSL-UHFFFAOYSA-N 0.000 description 1
• LTOSWGNOTRAAQN-HNNXBMFYSA-N C(CCC)C=1N(C(C(=C(N=1)O)C(=O)OCC)=O)[C@@H](CC)C1=CC=CC=C1 Chemical compound C(CCC)C=1N(C(C(=C(N=1)O)C(=O)OCC)=O)[C@@H](CC)C1=CC=CC=C1 LTOSWGNOTRAAQN-HNNXBMFYSA-N 0.000 description 1
• PKQDWVJCISVGRT-UHFFFAOYSA-N C1(CC1)CC=1N(C(=C(C(N=1)=O)C=1OC(=NN=1)CC1=NC(=NO1)C1=NC=CC=C1)O)C1=C(C=CC=C1OC)OC Chemical compound C1(CC1)CC=1N(C(=C(C(N=1)=O)C=1OC(=NN=1)CC1=NC(=NO1)C1=NC=CC=C1)O)C1=C(C=CC=C1OC)OC PKQDWVJCISVGRT-UHFFFAOYSA-N 0.000 description 1
• HQLUWSDBXJXXHQ-UHFFFAOYSA-N C1(CC1)CCC=1N(C(=C(C(N=1)=O)C1=NN=C(O1)CC(=O)O)O)C1=C(C=CC=C1OC)OC Chemical compound C1(CC1)CCC=1N(C(=C(C(N=1)=O)C1=NN=C(O1)CC(=O)O)O)C1=C(C=CC=C1OC)OC HQLUWSDBXJXXHQ-UHFFFAOYSA-N 0.000 description 1
• ZJPLFQZENSGJNK-UHFFFAOYSA-N C1(CC1)CCC=1N(C(=C(C(N=1)=O)C1=NN=C(O1)CN(C(C1=NC=CC=C1)=O)C)O)C1=C(C=CC=C1OC)OC Chemical compound C1(CC1)CCC=1N(C(=C(C(N=1)=O)C1=NN=C(O1)CN(C(C1=NC=CC=C1)=O)C)O)C1=C(C=CC=C1OC)OC ZJPLFQZENSGJNK-UHFFFAOYSA-N 0.000 description 1
• HUVPWOHNRRPVEF-UHFFFAOYSA-N C1(CC1)CCC=1N(C(=C(C(N=1)=O)C1=NN=C(O1)CNC(=O)C=1C=NC=CC=1)O)C1=C(C=CC=C1OC)OC Chemical compound C1(CC1)CCC=1N(C(=C(C(N=1)=O)C1=NN=C(O1)CNC(=O)C=1C=NC=CC=1)O)C1=C(C=CC=C1OC)OC HUVPWOHNRRPVEF-UHFFFAOYSA-N 0.000 description 1
• XVQSKPPFAQSYIK-UHFFFAOYSA-N C1(CC1)CCC=1N(C(=C(C(N=1)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)F)O)C1=C(C=CC=C1OC)OC Chemical compound C1(CC1)CCC=1N(C(=C(C(N=1)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)F)O)C1=C(C=CC=C1OC)OC XVQSKPPFAQSYIK-UHFFFAOYSA-N 0.000 description 1
• MTAALOMRBORGMH-UHFFFAOYSA-N C1(CCCC1)C=1N(C(=C(C(N=1)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)F)O)C1=C(C=CC=C1OC)OC Chemical compound C1(CCCC1)C=1N(C(=C(C(N=1)=O)C=1OC(=NN=1)CC1=NC=C(C=C1)F)O)C1=C(C=CC=C1OC)OC MTAALOMRBORGMH-UHFFFAOYSA-N 0.000 description 1
• WOCYBAANEBMZEH-UHFFFAOYSA-N C1(CCCC1)C=1N(C(=C(C(N=1)=O)C=1OC(=NN=1)CC=1C=NC(=CC=1)C)O)C1=C(C=CC=C1OC)OC Chemical compound C1(CCCC1)C=1N(C(=C(C(N=1)=O)C=1OC(=NN=1)CC=1C=NC(=CC=1)C)O)C1=C(C=CC=C1OC)OC WOCYBAANEBMZEH-UHFFFAOYSA-N 0.000 description 1
• PVAJDEVOHOZSCM-UHFFFAOYSA-N C1(CCCCC1)NC(=O)N.C(C)(=O)C1=CC=CC=C1 Chemical compound C1(CCCCC1)NC(=O)N.C(C)(=O)C1=CC=CC=C1 PVAJDEVOHOZSCM-UHFFFAOYSA-N 0.000 description 1
• 125000006538 C11 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• CGDWENMAICPPOT-UHFFFAOYSA-N CCCCC1=NC(=O)C(C(=O)OCC)=C(O)N1C1=C(OC)C=CC=C1OC Chemical compound CCCCC1=NC(=O)C(C(=O)OCC)=C(O)N1C1=C(OC)C=CC=C1OC CGDWENMAICPPOT-UHFFFAOYSA-N 0.000 description 1
• PIGNZTTWTGIFPO-UHFFFAOYSA-N CCCCC1=NC(=O)C(C2=NN=C(CC3=CC=C(Cl)C=C3)O2)=C(O)N1C1=C(OC)C=CC=C1OC Chemical compound CCCCC1=NC(=O)C(C2=NN=C(CC3=CC=C(Cl)C=C3)O2)=C(O)N1C1=C(OC)C=CC=C1OC PIGNZTTWTGIFPO-UHFFFAOYSA-N 0.000 description 1
• RZEBYIMLNDECPJ-UHFFFAOYSA-N CCCCC1=NC(=O)C(C2=NN=C(CC3=NOC4=C3C=CC=C4)O2)=C(O)N1C1=C(OC)C=CC=C1C Chemical compound CCCCC1=NC(=O)C(C2=NN=C(CC3=NOC4=C3C=CC=C4)O2)=C(O)N1C1=C(OC)C=CC=C1C RZEBYIMLNDECPJ-UHFFFAOYSA-N 0.000 description 1
• BKDMGYZEERFRNX-UHFFFAOYSA-N CCCCC1=NC(O)=C(Br)C(=O)N1C1=C(OC)C=CC=C1OC Chemical compound CCCCC1=NC(O)=C(Br)C(=O)N1C1=C(OC)C=CC=C1OC BKDMGYZEERFRNX-UHFFFAOYSA-N 0.000 description 1
• TZALDFIRMLWQQA-UHFFFAOYSA-N COC1=CC=CC(OC)=C1N1C(O)=C(C2=NN=C(CC3=NOC4=C3C=CC=C4)O2)C(=O)N=C1CCC=C Chemical compound COC1=CC=CC(OC)=C1N1C(O)=C(C2=NN=C(CC3=NOC4=C3C=CC=C4)O2)C(=O)N=C1CCC=C TZALDFIRMLWQQA-UHFFFAOYSA-N 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 229930186147 Cephalosporin Natural products 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
• 101800001982 Cholecystokinin Proteins 0.000 description 1
• 102100025841 Cholecystokinin Human genes 0.000 description 1
• 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
• 229920001268 Cholestyramine Polymers 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• XEKLAZRFRALLPR-UHFFFAOYSA-N ClC1=C(C=C(C=C1)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)COCC)=O)F Chemical compound ClC1=C(C=C(C=C1)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)COCC)=O)F XEKLAZRFRALLPR-UHFFFAOYSA-N 0.000 description 1
• SBXALHJIIWYLNM-UHFFFAOYSA-N ClC1=CC(=C(C=C1)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)COC(C)C)=O)F Chemical compound ClC1=CC(=C(C=C1)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)COC(C)C)=O)F SBXALHJIIWYLNM-UHFFFAOYSA-N 0.000 description 1
• NUXJOCJWIGOOBD-UHFFFAOYSA-N ClC1=CC=C(C=C1)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1CC)CC)COCC)=O Chemical compound ClC1=CC=C(C=C1)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1CC)CC)COCC)=O NUXJOCJWIGOOBD-UHFFFAOYSA-N 0.000 description 1
• NQZHRUYQEGZCEY-UHFFFAOYSA-N ClC1=CC=C(C=C1)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)CCC1CC1)=O Chemical compound ClC1=CC=C(C=C1)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)CCC1CC1)=O NQZHRUYQEGZCEY-UHFFFAOYSA-N 0.000 description 1
• KZWMVINSVSZGFZ-UHFFFAOYSA-N ClC1=CC=C(C=C1)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)COC(C)C)=O Chemical compound ClC1=CC=C(C=C1)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)COC(C)C)=O KZWMVINSVSZGFZ-UHFFFAOYSA-N 0.000 description 1
• OGGDYGWQZBLRGO-UHFFFAOYSA-N ClC1=CC=C(C=N1)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)C1CCCC1)=O Chemical compound ClC1=CC=C(C=N1)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)C1CCCC1)=O OGGDYGWQZBLRGO-UHFFFAOYSA-N 0.000 description 1
• GMOUAWBHSYBCCK-UHFFFAOYSA-N ClC=1C=C(C(=NC=1)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)C1CCC1)=O)F Chemical compound ClC=1C=C(C(=NC=1)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)C1CCC1)=O)F GMOUAWBHSYBCCK-UHFFFAOYSA-N 0.000 description 1
• DNJOWKHMPNCZNP-UHFFFAOYSA-N ClC=1C=C(C(=NC=1)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)C1CCCC1)=O)F Chemical compound ClC=1C=C(C(=NC=1)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)C1CCCC1)=O)F DNJOWKHMPNCZNP-UHFFFAOYSA-N 0.000 description 1
• MCXIJGWFHIBMAE-UHFFFAOYSA-N ClC=1C=CC(=NC=1)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)C1CCCC1)=O Chemical compound ClC=1C=CC(=NC=1)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)C1CCCC1)=O MCXIJGWFHIBMAE-UHFFFAOYSA-N 0.000 description 1
• 206010009807 Coarctation of the aorta Diseases 0.000 description 1
• 229920002911 Colestipol Polymers 0.000 description 1
• 208000003890 Coronary Vasospasm Diseases 0.000 description 1
• 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
• 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
• FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 102000015554 Dopamine receptor Human genes 0.000 description 1
• 108050004812 Dopamine receptor Proteins 0.000 description 1
• 208000032928 Dyslipidaemia Diseases 0.000 description 1
• 208000000059 Dyspnea Diseases 0.000 description 1
• 206010013975 Dyspnoeas Diseases 0.000 description 1
• 208000037487 Endotoxemia Diseases 0.000 description 1
• YZGQDNOIGFBYKF-UHFFFAOYSA-N Ethoxyacetic acid Chemical compound CCOCC(O)=O YZGQDNOIGFBYKF-UHFFFAOYSA-N 0.000 description 1
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
• HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
• 108010011459 Exenatide Proteins 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 102400001370 Galanin Human genes 0.000 description 1
• 101800002068 Galanin Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 102000034354 Gi proteins Human genes 0.000 description 1
• 108091006101 Gi proteins Proteins 0.000 description 1
• FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 244000020551 Helianthus annuus Species 0.000 description 1
• 235000003222 Helianthus annuus Nutrition 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 229940122199 Insulin secretagogue Drugs 0.000 description 1
• 229940122355 Insulin sensitizer Drugs 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• 102000000853 LDL receptors Human genes 0.000 description 1
• 108010001831 LDL receptors Proteins 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 102000016267 Leptin Human genes 0.000 description 1
• 108010092277 Leptin Proteins 0.000 description 1
• 239000002841 Lewis acid Substances 0.000 description 1
• 229940127470 Lipase Inhibitors Drugs 0.000 description 1
• 208000017170 Lipid metabolism disease Diseases 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
• 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
• 101710151321 Melanostatin Proteins 0.000 description 1
• IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
• HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 1
• 150000001204 N-oxides Chemical class 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 102400000064 Neuropeptide Y Human genes 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 1
• 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• JWAVLGXGTJURLG-UHFFFAOYSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)C(C(C)C)C1=CC=CC=C1)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)C(C(C)C)C1=CC=CC=C1)=O JWAVLGXGTJURLG-UHFFFAOYSA-N 0.000 description 1
• XKYYTVIVVBXXAX-UHFFFAOYSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)C(C)C1=CC=NC=C1)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)C(C)C1=CC=NC=C1)=O XKYYTVIVVBXXAX-UHFFFAOYSA-N 0.000 description 1
• PXXVYYFPXOMCGB-INIZCTEOSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)[C@@H](C)C1=CC(=CC=C1)OC)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)[C@@H](C)C1=CC(=CC=C1)OC)=O PXXVYYFPXOMCGB-INIZCTEOSA-N 0.000 description 1
• SUVIMHBRFFFHOK-INIZCTEOSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)[C@@H](C)C1=CC=CC=C1)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)[C@@H](C)C1=CC=CC=C1)=O SUVIMHBRFFFHOK-INIZCTEOSA-N 0.000 description 1
• SPVAILQIYQDACK-FQEVSTJZSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)[C@@H](CC)C1=CC=CC=C1)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)[C@@H](CC)C1=CC=CC=C1)=O SPVAILQIYQDACK-FQEVSTJZSA-N 0.000 description 1
• VZKQNEGZUIOKJJ-NRFANRHFSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)[C@@H](CCC)C1=CC=CC=C1)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)[C@@H](CCC)C1=CC=CC=C1)=O VZKQNEGZUIOKJJ-NRFANRHFSA-N 0.000 description 1
• AQHJYTPNGFNCCY-FQEVSTJZSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)[C@@H](COC)C1=CC=CC=C1)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)[C@@H](COC)C1=CC=CC=C1)=O AQHJYTPNGFNCCY-FQEVSTJZSA-N 0.000 description 1
• SUVIMHBRFFFHOK-MRXNPFEDSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)[C@H](C)C1=CC=CC=C1)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)[C@H](C)C1=CC=CC=C1)=O SUVIMHBRFFFHOK-MRXNPFEDSA-N 0.000 description 1
• SPVAILQIYQDACK-HXUWFJFHSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)[C@H](CC)C1=CC=CC=C1)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)[C@H](CC)C1=CC=CC=C1)=O SPVAILQIYQDACK-HXUWFJFHSA-N 0.000 description 1
• AQHJYTPNGFNCCY-HXUWFJFHSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)[C@H](COC)C1=CC=CC=C1)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N(C(=NC=1O)CCCC)[C@H](COC)C1=CC=CC=C1)=O AQHJYTPNGFNCCY-HXUWFJFHSA-N 0.000 description 1
• TXAOBLGIIXWHHK-UHFFFAOYSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1C)OC)CCC=C)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1C)OC)CCC=C)=O TXAOBLGIIXWHHK-UHFFFAOYSA-N 0.000 description 1
• SZUGNRWQEBUYCC-UHFFFAOYSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1C1CC1)C1CC1)COC(C)C)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1C1CC1)C1CC1)COC(C)C)=O SZUGNRWQEBUYCC-UHFFFAOYSA-N 0.000 description 1
• CKJSZGAMWSSVEK-UHFFFAOYSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1CC)CC)COCC)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1CC)CC)COCC)=O CKJSZGAMWSSVEK-UHFFFAOYSA-N 0.000 description 1
• WLVUSKYEOZIUJN-UHFFFAOYSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1Cl)Cl)CCCC)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1Cl)Cl)CCCC)=O WLVUSKYEOZIUJN-UHFFFAOYSA-N 0.000 description 1
• YGCSWOJICGKXQF-UHFFFAOYSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)CCCC(F)(F)F)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)CCCC(F)(F)F)=O YGCSWOJICGKXQF-UHFFFAOYSA-N 0.000 description 1
• KODVMOAEXIPLCA-UHFFFAOYSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)COC(C)C)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)COC(C)C)=O KODVMOAEXIPLCA-UHFFFAOYSA-N 0.000 description 1
• PWINAHJVANBCCW-UHFFFAOYSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)COCC)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C1=C(C=CC=C1OC)OC)COCC)=O PWINAHJVANBCCW-UHFFFAOYSA-N 0.000 description 1
• YUNYXHODEFLQAS-UHFFFAOYSA-N O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C=1C(=NC=NC=1OC)OC)CCCC)=O Chemical compound O1N=C(C2=C1C=CC=C2)CC1=NN=C(O1)C=1C(N=C(N(C=1O)C=1C(=NC=NC=1OC)OC)CCCC)=O YUNYXHODEFLQAS-UHFFFAOYSA-N 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 102000023984 PPAR alpha Human genes 0.000 description 1
• 108010016731 PPAR gamma Proteins 0.000 description 1
• 108010044210 PPAR-beta Proteins 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
• 108010081690 Pertussis Toxin Proteins 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• 206010037423 Pulmonary oedema Diseases 0.000 description 1
• 108700018615 Pyr(1)- apelin 13 Proteins 0.000 description 1
• KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 229940100389 Sulfonylurea Drugs 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 244000299461 Theobroma cacao Species 0.000 description 1
• 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
• 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
• 229940123464 Thiazolidinedione Drugs 0.000 description 1
• JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 206010047139 Vasoconstriction Diseases 0.000 description 1
• 206010047141 Vasodilatation Diseases 0.000 description 1
• FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
• CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical group [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
• 229960002632 acarbose Drugs 0.000 description 1
• XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
• PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
• WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 206010000891 acute myocardial infarction Diseases 0.000 description 1
• 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000000048 adrenergic agonist Substances 0.000 description 1
• 239000000785 adrenergic beta-1 receptor agonist Substances 0.000 description 1
• 239000000808 adrenergic beta-agonist Substances 0.000 description 1
• 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 239000005456 alcohol based solvent Substances 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 239000002170 aldosterone antagonist Substances 0.000 description 1
• 150000001335 aliphatic alkanes Chemical class 0.000 description 1
• 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
• 150000008041 alkali metal carbonates Chemical class 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 125000006177 alkyl benzyl group Chemical group 0.000 description 1
• 125000004414 alkyl thio group Chemical group 0.000 description 1
• 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 239000003957 anion exchange resin Substances 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
• 230000002205 anti-dementic effect Effects 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 230000002253 anti-ischaemic effect Effects 0.000 description 1
• 229940125682 antidementia agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 229940127218 antiplatelet drug Drugs 0.000 description 1
• SVWSKJCJNAIKNH-MJZUAXFLSA-N apelin-17 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](N)CCCCN)C1=CN=CN1 SVWSKJCJNAIKNH-MJZUAXFLSA-N 0.000 description 1
• BVTLGARMSLXAHI-VDEROMQGSA-N apelin-36 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)C(C)C)C1=CN=CN1 BVTLGARMSLXAHI-VDEROMQGSA-N 0.000 description 1
• 239000002830 appetite depressant Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 229910052786 argon Inorganic materials 0.000 description 1
• 150000004982 aromatic amines Chemical group 0.000 description 1
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 229960004365 benzoic acid Drugs 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• 229960000516 bezafibrate Drugs 0.000 description 1
• IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
• 239000003613 bile acid Substances 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
• 230000005587 bubbling Effects 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
• 210000004900 c-terminal fragment Anatomy 0.000 description 1
• 230000001593 cAMP accumulation Effects 0.000 description 1
• 230000003491 cAMP production Effects 0.000 description 1
• 235000001046 cacaotero Nutrition 0.000 description 1
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
• 229910000024 caesium carbonate Inorganic materials 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 150000001735 carboxylic acids Chemical group 0.000 description 1
• 230000009787 cardiac fibrosis Effects 0.000 description 1
• 210000004413 cardiac myocyte Anatomy 0.000 description 1
• 230000003293 cardioprotective effect Effects 0.000 description 1
• 230000009084 cardiovascular function Effects 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 229940124587 cephalosporin Drugs 0.000 description 1
• 150000001780 cephalosporins Chemical class 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
• 229960003291 chlorphenamine Drugs 0.000 description 1
• 229960001761 chlorpropamide Drugs 0.000 description 1
• 229940107137 cholecystokinin Drugs 0.000 description 1
• 229940107161 cholesterol Drugs 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
• 229950009226 ciglitazone Drugs 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 208000035850 clinical syndrome Diseases 0.000 description 1
• 229960001214 clofibrate Drugs 0.000 description 1
• KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
• AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
• GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
• 229960002604 colestipol Drugs 0.000 description 1
• 239000013066 combination product Substances 0.000 description 1
• 229940127555 combination product Drugs 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
• 201000011634 coronary artery vasospasm Diseases 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• ZBCKWHYWPLHBOK-UHFFFAOYSA-N cyclohexylphosphane Chemical compound PC1CCCCC1 ZBCKWHYWPLHBOK-UHFFFAOYSA-N 0.000 description 1
• 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• DIOQZVSQGTUSAI-NJFSPNSNSA-N decane Chemical compound CCCCCCCCC[14CH3] DIOQZVSQGTUSAI-NJFSPNSNSA-N 0.000 description 1
• 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 150000001975 deuterium Chemical group 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 229960004597 dexfenfluramine Drugs 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• 102000038379 digestive enzymes Human genes 0.000 description 1
• 108091007734 digestive enzymes Proteins 0.000 description 1
• 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
• NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 230000001882 diuretic effect Effects 0.000 description 1
• DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 230000008406 drug-drug interaction Effects 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 150000002085 enols Chemical group 0.000 description 1
• AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
• 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
• PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 229960001519 exenatide Drugs 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 238000013213 extrapolation Methods 0.000 description 1
• 229960002297 fenofibrate Drugs 0.000 description 1
• YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
• 229940125753 fibrate Drugs 0.000 description 1
• 239000002319 fibrinogen receptor antagonist Substances 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 125000003709 fluoroalkyl group Chemical group 0.000 description 1
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 239000003205 fragrance Substances 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 229960004580 glibenclamide Drugs 0.000 description 1
• 229960004346 glimepiride Drugs 0.000 description 1
• WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
• 229960001381 glipizide Drugs 0.000 description 1
• ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
• 229960003468 gliquidone Drugs 0.000 description 1
• 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 229960002989 glutamic acid Drugs 0.000 description 1
• 229940120105 glynase Drugs 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 125000004995 haloalkylthio group Chemical group 0.000 description 1
• 208000038002 heart failure with reduced ejection fraction Diseases 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000005980 hexynyl group Chemical group 0.000 description 1
• 238000004896 high resolution mass spectrometry Methods 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 102000047215 human APLNR Human genes 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 150000004678 hydrides Chemical class 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 230000003301 hydrolyzing effect Effects 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
• 150000004679 hydroxides Chemical class 0.000 description 1
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• 201000001421 hyperglycemia Diseases 0.000 description 1
• 201000008980 hyperinsulinism Diseases 0.000 description 1
• 230000001146 hypoxic effect Effects 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 208000001286 intracranial vasospasm Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• LAQPNDIUHRHNCV-UHFFFAOYSA-N isophthalonitrile Chemical compound N#CC1=CC=CC(C#N)=C1 LAQPNDIUHRHNCV-UHFFFAOYSA-N 0.000 description 1
• 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 125000000468 ketone group Chemical group 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
• 229940039781 leptin Drugs 0.000 description 1
• 150000007517 lewis acids Chemical class 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
• 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 230000007721 medicinal effect Effects 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
• 229960003105 metformin Drugs 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
• 229960001110 miglitol Drugs 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 239000002395 mineralocorticoid Substances 0.000 description 1
• 239000002394 mineralocorticoid antagonist Substances 0.000 description 1
• 230000000116 mitigating effect Effects 0.000 description 1
• SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
• FSUMZUVANZAHBW-UHFFFAOYSA-N n,n-dimethoxyaniline Chemical compound CON(OC)C1=CC=CC=C1 FSUMZUVANZAHBW-UHFFFAOYSA-N 0.000 description 1
• SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
• DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
• NSBIQPJIWUJBBX-UHFFFAOYSA-N n-methoxyaniline Chemical compound CONC1=CC=CC=C1 NSBIQPJIWUJBBX-UHFFFAOYSA-N 0.000 description 1
• OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 239000006070 nanosuspension Substances 0.000 description 1
• 229960000698 nateglinide Drugs 0.000 description 1
• OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
• 230000003880 negative regulation of appetite Effects 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 150000002825 nitriles Chemical class 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000002664 nootropic agent Substances 0.000 description 1
• 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
• URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
• 239000012038 nucleophile Substances 0.000 description 1
• NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
• 229960001243 orlistat Drugs 0.000 description 1
• 229910052762 osmium Inorganic materials 0.000 description 1
• SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• GGMAXEWLXWJGSF-PEWBXTNBSA-N p-Glu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1NC(=O)CC1)C1=CN=CN1 GGMAXEWLXWJGSF-PEWBXTNBSA-N 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
• WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
• 125000005981 pentynyl group Chemical group 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 230000036513 peripheral conductance Effects 0.000 description 1
• 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 229950000688 phenothiazine Drugs 0.000 description 1
• 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
• 229960003562 phentermine Drugs 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
• 229960000395 phenylpropanolamine Drugs 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
• 229940081066 picolinic acid Drugs 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229960005095 pioglitazone Drugs 0.000 description 1
• JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 1
• XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
• 125000005936 piperidyl group Chemical group 0.000 description 1
• LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
• 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
• 239000003880 polar aprotic solvent Substances 0.000 description 1
• 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
• 229910000160 potassium phosphate Inorganic materials 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 229960003611 pramlintide Drugs 0.000 description 1
• 108010029667 pramlintide Proteins 0.000 description 1
• NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
• 229960002847 prasterone Drugs 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000036316 preload Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
• 229960003912 probucol Drugs 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 108010070701 procolipase Proteins 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 230000004224 protection Effects 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000007026 protein scission Effects 0.000 description 1
• 235000018102 proteins Nutrition 0.000 description 1
• 208000005333 pulmonary edema Diseases 0.000 description 1
• 125000002755 pyrazolinyl group Chemical group 0.000 description 1
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000001422 pyrrolinyl group Chemical group 0.000 description 1
• 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
• 229960004622 raloxifene Drugs 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 230000033300 receptor internalization Effects 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
• 229960002354 repaglinide Drugs 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• 238000011808 rodent model Methods 0.000 description 1
• 229960004586 rosiglitazone Drugs 0.000 description 1
• 229910052707 ruthenium Inorganic materials 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 239000012047 saturated solution Substances 0.000 description 1
• QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
• 229960004937 saxagliptin Drugs 0.000 description 1
• 108010033693 saxagliptin Proteins 0.000 description 1
• 238000007789 sealing Methods 0.000 description 1
• 239000008299 semisolid dosage form Substances 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 208000013220 shortness of breath Diseases 0.000 description 1
• UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
• 229960004425 sibutramine Drugs 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 230000007727 signaling mechanism Effects 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
• MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
• 229960004034 sitagliptin Drugs 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
• 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 238000007614 solvation Methods 0.000 description 1
• 239000011877 solvent mixture Substances 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 238000010922 spray-dried dispersion Methods 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 125000000547 substituted alkyl group Chemical group 0.000 description 1
• 229950000244 sulfanilic acid Drugs 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 230000009469 supplementation Effects 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• JYRWUSXRTGACLY-UHFFFAOYSA-N tert-butyl 4-[[3-(4-methylsulfonylphenyl)-[1,2]oxazolo[4,5-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=NC=NC2=C1ON=C2C1=CC=C(S(C)(=O)=O)C=C1 JYRWUSXRTGACLY-UHFFFAOYSA-N 0.000 description 1
• FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
• ZGNPLWZYVAFUNZ-UHFFFAOYSA-N tert-butylphosphane Chemical compound CC(C)(C)P ZGNPLWZYVAFUNZ-UHFFFAOYSA-N 0.000 description 1
• DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 125000005309 thioalkoxy group Chemical group 0.000 description 1
• 125000005403 thiohaloalkoxy group Chemical group 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 230000007838 tissue remodeling Effects 0.000 description 1
• 229960005371 tolbutamide Drugs 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 229910052723 transition metal Inorganic materials 0.000 description 1
• 150000003624 transition metals Chemical class 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
• INQOMBQAUSQDDS-FIBGUPNXSA-N trideuterio(iodo)methane Chemical compound [2H]C([2H])([2H])I INQOMBQAUSQDDS-FIBGUPNXSA-N 0.000 description 1
• GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
• 229960001641 troglitazone Drugs 0.000 description 1
• GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
• 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 210000003556 vascular endothelial cell Anatomy 0.000 description 1
• 230000025033 vasoconstriction Effects 0.000 description 1
• 229940124549 vasodilator Drugs 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 239000011715 vitamin B12 Substances 0.000 description 1
• 239000011726 vitamin B6 Substances 0.000 description 1
• 229960001729 voglibose Drugs 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
• 125000006839 xylylene group Chemical group 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1